Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4308-4310

  Gomez J ^a   Canovas, E ^a   Banos V ^a   Martinez L ^a   Garcia E ^a   Hernandez Torres A ^a   Canteras, M ^b   Ruiz, J ^a   Medina, M ^a   Martinez P ^a   Canovas, A ^a   Soriano, A ^c   Clavel, M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CIPROFLOXACIN; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TRIMETHOPRIM;

AGE DISTRIBUTION; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BONE RADIOGRAPHY; COHORT ANALYSIS; DISEASE DURATION; DISEASE MARKER; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIP PROSTHESIS; HUMAN; KNEE PROSTHESIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MUCOCUTANEOUS CANDIDIASIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS INFECTION; PROSTHETIC JOINT INFECTION; SALVAGE THERAPY; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HIP PROSTHESIS; HUMANS; KNEE PROSTHESIS; MALE; MIDDLE AGED; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; SALVAGE THERAPY;

EID: 80051803903     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00352-11     Document Type: Article

References (23)

1. Barberan, J., et al. 2006. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am. J. Med. 119:7-10.
2. Bassetti, M., et al. 2005. Linezolid in the treatment of Gram-positive prosthetic joint infections. J. Antimicrob. Chemother. 55:387-390. (Pubitemid 40425467)
3. Byren, I., et al. 2009. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): Antibiotic duration and outcome. J. Antimicrob. Chemother. 63:1264-1271.
4. Falagas, M E, I I Siempos, P J Papagelopoulos, and K Z Vardakas. 2007. Linezolid for the treatment of adults with bone and joint infections. Int. J. Antimicrob. Agents 29:233-239. (Pubitemid 46240739)
5. Ferry, T., et al. 2010. Risk factors for treatment failure in orthopedic devicerelated methicillin-resistant Staphylococcus aureus infection. Eur. J. Clin. Microbiol. Infect. Dis. 29:171-180.
6. Gandelman, K., et al. 2010. Unexpected effect of rifampin on the pharmacokinetics of linezolid: In silico and in vitro approaches to explain its mechanism. J. Clin. Pharmacol. 51:229-236.
7. Garrabou, G., et al. 2007. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother. 51:962-967. (Pubitemid 46355281)
8. Jones, R N, S. Kohno, Y. Ono, J E Ross, and K. Yanagihara. 2009. ZAAPS International Surveillance Program (2007) for linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64:191-201.
9. Kilgus, D J, D J Howe, and A. Strang. 2002. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin. Orthop. Rel. Res. 404:116-124. (Pubitemid 35351060)
10. Kutscha-Lissberg, F., U. Hebler, G. Muhr, and M. Koller. 2003. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47:3964-3966. (Pubitemid 37485016)
11. Laffer, R R, P. Graber, P E Ochsner, and W. Zimmerli. 2006. Outcome of prosthetic knee-associated infection: Evaluation of 40 consecutive episodes at a single centre. Clin. Microbiol. Infect. 12:433-439.
12. Legout, L., et al. 2010. Tolerability of prolonged linezolid therapy in bone and joint infection: Protective effect of rifampicin on the occurrence of anaemia? J. Antimicrob. Chemother. 65:2224-2230.
13. Nguyen, S., et al. 2009. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin. Microbiol. Infect. 15:1163-1169.
14. Pea, F., et al. 2006. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin. Infect. Dis. 42:434-435. (Pubitemid 43122327)
15. Salgado, C D, S. Dash, J R Cantey, and C E Marculescu. 2007. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin. Orthop. Relat. Res. 461:48-53. (Pubitemid 47344093)
16. Soriano, A., et al. 2006. Treatment of acute post-surgical infection of joint arthroplasty. Clin. Microbiol. Infect. 12:930-933. (Pubitemid 44151298)
17. Soriano, A., et al. 2007. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis. 26:353-356. (Pubitemid 46716796)
18. Soriano, A., O. Miro, and J. Mensa. 2005. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353:2305-2306.
19. Soriano, A., et al. 2007. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob. Agents Chemother. 51:2559-2563. (Pubitemid 47047337)
20. Tsukayama, D T, V M Goldberg, and R. Kyle. 2003. Diagnosis and management of infection after total knee arthroplasty. J. Bone Joint Surg. Am. 85A(Suppl. 1):S75-S80.
21. Vilchez, F., et al. 2011. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin. Microbiol. Infect. 17:439-444.
22. Zimmerli, W., A. Trampuz, and P E Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
23. Zimmerli, W., A F Widmer, M. Blatter, R. Frei, and P E Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. JAMA 279:1537-1541. (Pubitemid 28233008)